Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study
Fluge O, Bruland O, Risa K +7 more2011PLoS ONEJournal Article
Immune/InnateNeurological
Abstract
Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the anti-CD20 antibody Rituximab, which demonstrated significant clinical response in three CFS patients.
Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady
Related Papers
- CGRP sensory neurons promote tissue healing via neutrophils and macrophagesNature · 2024 · 2 shared tags
- Invited review: Mechanisms of hypophagia during diseaseJournal of Dairy Science · 2021 · 2 shared tags
- Diabetic complications and prospective immunotherapyFrontiers in Immunology · 2023 · 2 shared tags
- Gut-Brain Inflammation Due to Toxin-Activated Mast Cells and Microglia in Autism Spectrum DisorderPreprints.org · 2025 · 2 shared tags
- The Role of Adipokines and Myokines in the Pathogenesis of Different Obesity Phenotypes—New PerspectivesAntioxidants · 2023 · 2 shared tags
- Herbal Therapeutics for CIRS Biomarkers in Autism Spectrum Disorders: A Mechanistic and Molecular Approach for Neuroimmune Pathology in PediatricsMedical Research Archives · 2026 · 2 shared tags